| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 17.8 | 0.0 |
| Net income | 70.1 | -126.9 |
| EPS (diluted, $ a share) | $0.37 | $-0.74 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DNLI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Denali Therapeutics Inc.: key numbers
- Share price
- $18.08Close, Nov 16
- Market cap
- $2.9B
- Shares outstanding
- 160.29MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Denali Therapeutics Inc.
All →Denali Therapeutics Financial Results
Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.
- Term
- Q3 2026
“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”
Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics